Predictive Oncology (NASDAQ: POAI) CEO Discusses Subsidiaries’ Proprietary Tech, Innovative Media
CEO expects results that will “build the stock and raise the stock price” POAI focused on positioning TumorGenesis kits to manufacturers Helomics has largest database of its kind in the world, brings cutting-edge technology to cancer research During a recent NetworkNewsWire exclusive audio interview, Predictive Oncology (NASDAQ: POAI) CEO Carl Schwartz noted recent company milestones and outlined strategic goals. In addition, Schwartz provided key updates on the company’s four impressive subsidiaries: Skyline Medical, TumorGenesis, Soluble Biotech and Helomics. “I’m very encouraged. I think we’re moving right along. Things never go as fast as we would like them, and it can be…